This study will have a single arm: the patient on NPH will continue his treatment for 4 weeks, at the end of the NPH treatment, the patient will receive his CGM device for three days for glycemic holter, a switch to insulin glargine is started for a period of 12 weeks with a dose adjustment and a control of the glycemic balance by CGM for three days at the end of the study.
The NPH insulin vial is a 10 ml vial dosed at 100 IU/mL, The Glargen vial is in the form of a solution for injection, a 3 ml vial dosed at 100 IU/mL

开始日期2025-07-01

申办/合作机构

Les Laboratoires des Médicaments Stériles

CTRI/2025/04/085669

/ Not yet recruiting临床4期IIT

Comparative Efficacy and Safety of Glargine With Short-Acting Analog Versus NPH With Short-Acting Analog in Pulse Steroid Therapy-Induced Hyperglycemia - NIL

开始日期2025-06-02

申办/合作机构-

CTRI/2024/09/074053

/ Not yet recruitingN/AIIT

EFFICACY OF EARLY GLARGINE PLUS STANDARD IV INSULIN VERSUS STANDARD IV INSULIN IN PATIENTS WITH DIABETIC KETOACIDOSIS: A RANDOMISED CONTROLLED TRIAL - NIL

开始日期2024-09-30

申办/合作机构-

100 项与甘精胰岛素相关的临床结果

登录后查看更多信息

100 项与甘精胰岛素相关的转化医学

登录后查看更多信息

100 项与甘精胰岛素相关的专利（医药）

登录后查看更多信息

3,366

项与甘精胰岛素相关的文献（医药）

2025-08-11·DIABETES OBESITY & METABOLISM

Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.

Article

作者: Li, Xuan ; Amani, Mohammed E A ; Lauand, Felipe ; Alvarez, Agustina ; Adaş, Mine ; Khunti, Kamlesh ; Anderson, John ; Malik, Rayaz A ; Russo, Giuseppina

AIM:

To evaluate the effectiveness and safety of a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) over 24 months in people with type 2 diabetes (T2D).

METHODS:

In this retrospective, observational study, data were collected from the Optum Market Clarity® database in the United States. People with T2D aged ≥18 years, previously treated with oral antidiabetic drugs ± basal insulin or glucagon-like peptide-1 receptor agonists, who initiated iGlarLixi between 1 January 2017 and 31 March 2020 and received ≥1 iGlarLixi prescription were included. The primary outcome was change in HbA1c 24 months after starting iGlarLixi. Secondary outcomes included change in HbA1c from baseline, achievement of HbA1c <7%, change in body weight and rate of hypoglycaemia (defined as inpatient or outpatient claims, or blood glucose <70 mg/dL) every 3 months over 24 months.

RESULTS:

In total, 1685 people were included in this analysis (mean age, 58.4 years; 52.6% female). In the overall population, including imputed values, mean ± standard deviation (SD) baseline HbA1c (9.3 ± 1.8%) was reduced by 0.9% to 8.3 ± 1.8% at 24 months. A HbA1c target of <7% was achieved in 22.2% of people at 24 months. Mean ± SD body weight remained stable from baseline (102.1 ± 24.2 kg) to 24 months (101.9 ± 23.3 kg). The hypoglycaemia event rate was 16.1 per 100 person-years (P100PY) at baseline and decreased to 11.4 P100PY at 24 months.

CONCLUSIONS:

iGlarLixi initiation was associated with improved glycaemic control, without body weight change or increased hypoglycaemia over 24 months.

2025-08-01·JOURNAL OF CLINICAL PHARMACOLOGY

Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers

Article

作者: Chang, Yi Chien ; Jusko, William J.

Abstract:

This study compares the pharmacokinetics and efficacy of various subcutaneously (SC) dosed insulin analogs, including rapid‐acting, intermediate‐acting, long‐acting, and regular human insulin, using mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) models. These models were applied to data from euglycemic clamp studies in healthy volunteers, where insulin pharmacokinetics and its effects on glucose utilization were monitored. Data from published studies were digitized and modeled using MONOLIX (Version 2024). The PK model described insulin absorption via sequential first‐order processes and linear elimination. The PD effects were captured using a model combination of biophase, indirect, and receptor down‐regulation components. While PK parameters—especially absorption rates—varied between insulin types, a common set of nonlinear PD parameters was sought to account for dose‐related differences in glucose utilization. The maximum glucose stimulation () was 163, and the insulin concentration for a half‐maximal effect () were 1156 pmol/L for insulin lispro, regular human insulin, neutral protamine hagedorn (NPH) insulin, and insulin glargine; 674 pmol/L for insulin aspart; and 5335 pmol/L for insulin detemir. Insulin detemir showed similar overt effects as the other insulin types but with smaller clearances and lower potency. This mechanism‐based glucose–insulin model demonstrated that most insulin analogs exhibit similar receptor‐ and transporter‐related parameters. The model, with specific PK but unified PD parameters, may enable clinical optimization of insulin therapy by highlighting differences in pharmacokinetics and operating common intrinsic glucose utilization parameters.

2025-08-01·Diabetes Therapy

Insights on Hospitalisations from the Phase 3a ONWARDS 1–6 Trials of Once-Weekly Insulin Icodec

Article

作者: Bain, Stephen C ; Krogsdahl Bache, Julie ; Kellerer, Monika ; Salvesen-Sykes, Karen ; Philis-Tsimikas, Athena ; Fu, Ariel

INTRODUCTION:

The ONWARDS programme assessed the efficacy and safety of once-weekly insulin icodec (icodec) versus once-daily basal insulin comparators in type 2 diabetes (T2D) or type 1 diabetes (T1D). This post hoc exploratory analysis of ONWARDS 1-6 assessed the impact of icodec during and around hospitalisation.

METHODS:

ONWARDS 1-6 were randomised, two-arm, phase 3a trials (ClinicalTrials.gov: NCT04460885; NCT04770532; NCT04795531; NCT04880850; NCT04760626; NCT04848480). Adults with T2D (ONWARDS 1-5; n = 3765) and T1D (ONWARDS 6; n = 582) received icodec or once-daily comparators (insulin degludec, insulin glargine U100, insulin glargine U300). Hospitalised cases were analysed for: hospitalisation duration, icodec dose, self-measured blood glucose, glycated haemoglobin (HbA_1c) levels, and clinically significant and severe hypoglycaemia before, during, and after hospitalisation.

RESULTS:

Across trials, a similar number of participants receiving icodec (n = 152/2172) and once-daily comparators (n = 156/2175) were hospitalised. Median duration of hospital stay was similar between treatment groups (icodec, 5.0 days; once-daily comparators, 6.0 days); icodec dose remained fairly stable around hospitalisation. Most hospitalised participants completed the trial without permanently discontinuing treatment (icodec, 84.9%; once-daily comparators, 90.4%). Mean HbA_1c levels remained relatively stable over assessed time points for both treatment groups. Six participants receiving icodec (one with T2D; five with T1D) and three receiving once-daily comparators (one with T2D; two with T1D) reported clinically significant or severe hypoglycaemia during hospitalisation.

CONCLUSIONS:

Similar numbers of hospitalisations were reported in both treatment arms. Icodec treatment was continued during hospitalisation in most participants and did not appear to have an impact on glycaemic management or hypoglycaemia. This analysis suggests that once-weekly icodec could be managed in a similar way to once-daily basal insulin analogues during hospitalisation.

TRIAL REGISTRATION:

ClinicalTrials.gov identifiers, NCT04460885 (ONWARDS 1), NCT04770532 (ONWARDS 2), NCT04795531 (ONWARDS 3), NCT04880850 (ONWARDS 4), NCT04760626 (ONWARDS 5), NCT04848480 (ONWARDS 6).

353

项与甘精胰岛素相关的新闻（医药）

2025-08-07

·国际糖尿病idiabetes

三人行必有我师丨3个病例带您看懂口服疗效不佳T2DM患者的早联合破局法！

第二辑随着对2型糖尿病（T2DM）多重发病机制的深入理解和循证证据的不断积累，治疗理念已由“逐步加药”的传统路径转向“早期联合”控糖策略”[1-4]。在此背景下，《中国糖尿病防治指南（2024版）》[1]首次将基础胰岛素/GLP-1RA固定比例复方制剂（FRC）纳入口服药(OADs)控制不佳患者的起始胰岛素推荐，为临床控糖开辟新路径。那么，在实际诊疗中，面对OADs治疗效果不佳的T2DM患者，如何贯彻早期联合治疗理念？FRC治疗应在何时启动？剂量又该如何优化调整，以助力患者实现更快速、平稳的血糖达标？本期《国际糖尿病》特邀华中科技大学同济医学院附属同济医院陈茜医生、中南大学湘雅二医院许丰医生、保德县医疗集团闫磊医生，结合三个真实病例，深入解析并分享他们在临床一线践行“早联合、优控糖”策略的宝贵经验。病例亮点速递治疗挑战：三位患者糖尿病病程5~9年不等，血糖持续升高，糖化血红蛋白（HbA1c）在9.8%左右，提示单纯OADs治疗方案难以实现血糖达标。破局关键：及时起始甘精胰岛素利司那肽注射液治疗，快速降低空腹血糖（FPG）与餐后2小时血糖（2hPPG），同时可每天调整剂量，满足个体化需求。临床启示：对于OADs治疗血糖控制不佳的T2DM患者，甘精利司是较为理想的选择，不仅强效控糖、安全起始，有助于体重管理，而且用药便捷，显著提升患者依从性。病例一病例简介男，65岁。主诉：发现血糖升高9年，血糖控制不佳1月。 9年前体检时发现血糖升高，诊断为糖尿病。前几年患者未予重视，未予治疗。近三年开始药物治疗，目前应用二甲双胍、钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）降糖，近1月患者自测血糖控制不佳，FPG 11 mmol/L左右，伴肢端麻木，不伴泡沫尿，无明显视物模糊，无恶心、纳差，无胸闷、气短，以“T2DM”收住入院。高脂血症5年，未治疗。否认高血压、冠心病病史等，无糖尿病家族史。体格检查其他检查诊断 T2DM、T2DM性周围神经病、冠状动脉粥样硬化性心脏病、颈动脉粥样硬化、脑缺血灶、脂肪肝、高脂血症。入院治疗出院治疗门诊随访治疗体会多种OADs治疗血糖控制不佳，经住院强化治疗后选择甘精胰岛素利司那肽注射液(I)治疗，可显著改善患者的FPG及2hPPG，无明显胃肠道反应，且无低血糖发生；一天一针联合OADs方案得到了患者的认可和满意，增加依从性，可每天调整剂量，有助于实现血糖优质达标。病例二病例简介男，66岁。主诉：口干、多饮、多尿5年，夜尿增多半年。 5年前无明显诱因出现口干、多饮、多尿，体重下降，当地医院检查发现血糖升高，最高血糖不详，考虑“糖尿病”，予以西格列汀二甲双胍（Ⅱ）（西格列汀50 mg、二甲双胍850 mg）BID+恒格列净10 mg QD口服降糖，在家未规律监测血糖。近半年自觉口干加重，夜尿增多，每日饮水约2000 ml，夜尿1-2次/晚，不伴视物模糊、肢体麻木等症状。完善相关检查示血糖高、TG高、LDL-C高，以“糖尿病”收入我科。自起病以来，患者精神、睡眠、食欲尚可。大便正常，夜尿增多，体重未见明显变化。既往有血压升高病史，最高血压150/100 mmHg，未监测，未用药；否认糖尿病家族史。体格检查诊断 T2DM、高脂血症、高血压病1级。治疗方案及目标治疗经过 3个月后复查治疗体会糖尿病治疗已从以“降糖为主”的血糖管理阶段，迈入“以患者为中心”的综合管理时代。FRC凭借覆盖多重病理机制、简化方案、减轻用药负担等优势，契合这一治疗理念。甘精胰岛素利司那肽注射液兼具强效、便捷、安全、经济，为患者提供了更优的血糖管理选择。病例三病例简介女性，58岁。主诉：发现血糖高6年，双足麻木1年。 2020年无明显诱因出现口干、多饮，每日饮水约4 L，夜尿3-4次，无明显多食、体重下降，就诊于某中心医院检查FPG 9.8 mmol/L，诊断为“T2DM”，给予盐酸二甲双胍片、瑞格列奈片口服降糖，平时用药不规律，未监测血糖。 2024年出现双足麻木，无视物模糊、周身瘙痒、走路踩棉花感等症状，未重视。2025年6月健康体检显示FPG 11.5 mmol/L，遂就诊于我院。高血压病史2年，血压最高185/110 mmHg，口服厄贝沙坦150 mg QD治疗。母亲患有糖尿病。体格检查其他检查诊断 T2DM、高脂血症、血压病3级（极高危组）、轻度脂肪肝。治疗过程出院后随访治疗体会 T2DM患者在使用胰岛素治疗时，为了减少体重增加，建议使用甘精胰岛素利司那肽注射液。该方案可以达到一针双效的作用，并带来多重获益，包括强效降糖、不增加低血糖风险，有利于体重管理，以及简化治疗方案等。总结当前T2DM治疗正步入“早联合、早获益”的全新时代。对于OADs治疗血糖控制不佳的T2DM患者，需及时启动注射治疗，尤其是选择兼具多重机制、强效安全的降糖药物已成为打破控糖瓶颈的关键。在Lixilan-O-AP[5]和SoliD[6]研究等循证证据的有力支持下，《中国糖尿病防治指南（2024版）》不仅突出强调了早期联合治疗的必要性，更将FRC作为起始胰岛素治疗的重要推荐。本期三位临床专家通过详实的病例分享，深入诠释了如何将先进治疗理念转化为具体实践，从而切实提升治疗效果。他们的临床实践不仅再次验证了甘精胰岛素利司那肽注射液在T2DM早期联合治疗中的价值，也为广大医生提供了切实可行的治疗参考，推动糖尿病管理朝着更早期、更高效的方向迈进。参考文献：（上下滑动查看更多） [1]Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18. PMID: 31542292. [2]Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024 Jul 13;404(10448):145-155. doi: 10.1016/S0140-6736(24)00537-3. Epub 2024 May 18. PMID: 38772405. [3]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398.DOI:10.3760/cma.j.cn311282-20210304-00142. [4]中华医学会糖尿病学分会. 中国糖尿病防治指南（2024版）. 中华糖尿病杂志，2025，17(01):16-139. DOI:10.3760/cma.j.cn115791-20241203-00705. [5]Yang W, Dong X, Li Q, et al. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100?U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Diabetes Obes Metab. 2022 Aug;24(8):1522-1533. doi: 10.1111/dom.14722. Epub 2022 May 12. PMID: 35441412. [6]Liu M, Gu W, Chen L, et al. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial. Diabetes Obes Metab. 2024 Sep;26(9):3791-3800. doi: 10.1111/dom.15724. Epub 2024 Jun 22. PMID: 38922731. 专家简历陈茜华中科技大学同济医学院附属同济医院华中科技大学同济医学院附属同济医院内分泌科副主任医师主持国家自然科学基金一项，参与多项国家自然科学基金。在Journal of Clinical Endocrinology & Metabolism、Frontiers in Endocrinology、《中华糖尿病杂志》等杂志以第一作者身份发表论文10余篇。参与编写著作2部。许丰中南大学湘雅二医院主治医师、硕士研究生导师湖南省医学会骨质疏松和骨矿盐疾病专业委员会秘书湖南省老年医学学会临床精准医疗分会青年委员主持国家自然科学基金青年基金1项、省自然科学基金优秀青年基金和青年基金各1项第一作者/通讯作者在“Bioactive Materials”、” JAMA internal medicine”和“Journal of Pineal Research”等杂志发表SCI论文8篇、CSCD 1篇获得欧洲钙化组织协会（ECTS) “ECTS EAST-MEETS-WEST TRAVEL AWARD” 参与编写内分泌代谢病学（第4版） Journal of Pineal Research、Journal of Extracellular Vesicles和Science of the Total Environment等杂志审稿人闫磊保德县医疗集团保德县医疗集团内科主治医师忻州市医师协会内分泌分会委员山西省医师协会内分泌医师分会青年委员山西省高血压专业委员会委员山西省医师协会老年医师分会委员擅长：高血压、糖尿病、甲状腺疾病有丰富的临床经验。声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。 MAT-CN-2512825 最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

临床结果临床研究

2025-07-31

·生物制品圈

赛诺菲财报：上半年收入 219 亿美元，度普利尤单抗大卖 80 亿美元

7 月 31 日，赛诺菲发布 2025 年 Q2 和上半年财报：第二季度，销售额为 99.94 亿欧元（约 110 亿美元），增长 10.1%（按固定汇率计算，下同）；上半年，销售额为 198.89 亿欧元（约 219 亿美元），增长 9.9%。汇率按 2015 H1 平均汇率计算，1 欧元=1.1004 美元。从地区来看，上半年：美国市场收入最多，为 95.35 亿欧元，增长 16.4%；欧洲市场销售额为 41.44 亿欧元，增长 1.8%；中国市场收入为 13.88 亿欧元，增长 0.1%。截图来源：赛诺菲财报，下同制药业务新上市的 8 款药品，Q2 收入 8.97 亿欧元，增长 39.8%；上半年收入 17.44 亿欧元，增长 41.7%。其中，ALTUVIIIO（A 型血友病药物）增速最快，Q2 销售额为 2.91 亿欧元，增长 91.8%；上半年销售额为 5.42 亿欧元，增长 95.4%。自免药物领域，Dupixent（度普利尤单抗）上半年销售额为 73.12 亿欧元（约 80 亿美元），增长 20.7%。全球销售额的增长得益于所有获批适应症持续强劲的需求，包括特应性皮炎 (AD)、哮喘、伴有鼻息肉的慢性鼻窦炎、嗜酸性食管炎、结节性痒疹、慢性自发性荨麻疹、慢性阻塞性肺病 (COPD) 和大疱性类天疱疮。其它产品中，增速在 10% 以上的药物有三款，分别为：Lantus（甘精胰岛素），上半年销售额为 8.76 亿欧元，增长 17.7%；Toujeo（新一代基础胰岛素），上半年销售额为 6.92 亿欧元，增长 10.3%；Alprolix（B 型血友病药物），上半年销售额为 3.05 亿欧元，增长 13.7%。疫苗业务疫苗业务，Q2 销售额为 12.14 亿欧元，增长 10.3%；上半年销售额为 25.40 亿欧元，增长 10.9%。其中，脊髓灰质炎/百日咳/乙型流感嗜血杆菌 (PPH) 基础疫苗和加强疫苗是主力军，上半年创造了 13.61 亿欧元的收入，占到了疫苗收入的一半以上。管线进展赛诺菲目前在四大主要疾病领域（免疫学、罕见病、神经病学以及肿瘤学）和疫苗领域拥有 82 个在研项目，其中包括 40 个潜在的新药和疫苗。2025 下半年有望迎来多项里程碑进展。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

财报疫苗

2025-07-31

·BioSpace

Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025

iStock, wildpixel For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU. Sanofi CFO François Roger has expressed confidence that tariffs will have little impact on the company in 2025. Speaking on Sanofi’s second-quarter results earnings call, Roger said it is difficult to predict the impact because of uncertainty about what actions the White House will take. The trade deal with the European Union establishes a 15% tariff on imports from Europe, where Sanofi is based, but CEO Paul Hudson told investors it remains unclear whether “it’s a 15% tariff with a caveat or a 15-plus or a 15-less.” Amid the uncertainty, Sanofi has run various scenarios based on the proposals reported in the media to understand how tariffs could affect finances in 2025. The models suggest Sanofi has little to fear for now. “We did not factor it in our guidance, but it will have a limited impact on 2025 because we already have inventory in place in the U.S.,” Roger said. “With what we know today and what we read in the media, we don’t think that it will impact our guidance in any way for 2025.” Hudson fielded a broader question about tariffs, Most Favored Nation pricing and the balance in funding for innovative drugs between the U.S. and Europe. Hudson said nobody knows what will happen but Sanofi is prepared for delivering guidance this year, “so don’t feel we’re casual about it because we’re absolutely not.” President Donald Trump has accused other countries of freeloading, fueling debate about differences in drug prices and healthcare spending between the U.S. and EU. Hudson made the case for EU countries putting in place the budgets to ensure patients can access innovative therapies. “There’s a lot of people who could contribute to economies and GDP if medicines were made available to them,” Hudson said. “I’m as interested in budgets for health giving access to innovation for more patients as I am in the price conversation. We will see where it nets out. As a healthcare company, we’d like to see more patients get access.” Hudson was speaking after Sanofi reported 10.1% sales growth at a constant exchange rate in the second quarter. The growth led Sanofi to predict a high single-digit percentage increase in sales for the full year. Sanofi’s revised forecast narrows its 2025 outlook at the top end of the previously predicted mid-to-high single-digit range. Dupixent drove growth in the second quarter. Supported by its launch in chronic obstructive pulmonary disease, Dupixent sales grew more than 20% to 3.8 billion euros ($4.3 billion). Sales of three of Sanofi’s other main medicines—Lantus, Toujeo and Praluent—grew by 10% or more. Sanofi attributed the growth in sales of the long-acting insulin Lantus to windfall sales due to the unavailability of competing medicines. Sales of nine newly launched medicines and vaccines rose 47.3%. Hemophilia A therapy Altuviiio led the way with revenues of 291 million euros ($333 million), an increase of more than 90% over the second quarter of 2024. Sanofi said growth of Altuviiio, which the FDA approved in 2023, was driven by patients switching from older plasma-derived and recombinant factor medicines and to a lesser extent from non-factor drugs.

上市批准

100 项与甘精胰岛素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03250	甘精胰岛素	A10AE04	DB00047

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病	欧盟	Sanofi-Aventis Deutschland GmbH	2000-06-09
糖尿病	冰岛	Sanofi-Aventis Deutschland GmbH	2000-06-09
糖尿病	列支敦士登	Sanofi-Aventis Deutschland GmbH	2000-06-09
糖尿病	挪威	Sanofi-Aventis Deutschland GmbH	2000-06-09
1型糖尿病	美国	Sanofi-Aventis U.S. LLC	2000-04-20
2型糖尿病	美国	Sanofi-Aventis U.S. LLC	2000-04-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性心肌梗塞	临床3期	美国	Sanofi	2008-04-01
急性心肌梗塞	临床3期	阿根廷	Sanofi	2008-04-01
急性心肌梗塞	临床3期	巴西	Sanofi	2008-04-01
急性心肌梗塞	临床3期	加拿大	Sanofi	2008-04-01
急性心肌梗塞	临床3期	墨西哥	Sanofi	2008-04-01
糖尿病昏迷	临床3期	美国	Sanofi	2008-04-01
糖尿病昏迷	临床3期	阿根廷	Sanofi	2008-04-01
糖尿病昏迷	临床3期	巴西	Sanofi	2008-04-01
糖尿病昏迷	临床3期	加拿大	Sanofi	2008-04-01
糖尿病昏迷	临床3期	墨西哥	Sanofi	2008-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04980027 (SAFEGUARD Study, Pubmed \| Diabetes Ther)	临床4期	2型糖尿病	220	Insulin Glargine 300 U/ml	衊壓築繭淵窪艱鬱襯艱(繭衊鏇製構範餘醖鏇齋) = 網觸願衊製艱願獵製選襯襯艱鬱鑰蓋觸憲鬱淵 (壓鑰製憲窪繭鬱網鏇觸 ) 更多	积极	2025-05-08
NEWS 人工标引	N/A	2型糖尿病	568	甘精胰岛素U300 (初治)	鏇遞鑰壓夢鏇築鏇憲鏇(糧願醖網鏇選夢膚鹹廠) = 鹽遞範顧獵積衊壓衊醖鹽鬱衊餘選遞憲窪膚選 (淵願蓋衊廠襯廠壓構壓 ) 更多	积极	2024-11-19
				甘精胰岛素U300 (基础胰岛素转换)	鏇遞鑰壓夢鏇築鏇憲鏇(糧願醖網鏇選夢膚鹹廠) = 簾淵窪獵鹽構鹽鹽蓋鹹鹽鬱衊餘選遞憲窪膚選 (淵願蓋衊廠襯廠壓構壓 ) 更多
NCT03406000 (TOP1, Pubmed)	临床4期	1型糖尿病	-	Twice-daily basal insulin	憲淵範壓膚構遞顧製襯(齋築襯糧鹹艱夢衊鹽憲) = 壓齋蓋醖簾願簾窪廠鑰艱廠製壓夢糧壓選襯衊 (鏇網鹹繭觸艱範顧糧繭 ) 更多	积极	2024-07-09
NCT05109520 (Pubmed \| Diabetes Technol Ther)	N/A	1型糖尿病	-	Insulin Glargine 300 U/mL (Gla-300)	糧糧觸築蓋鹹艱製齋膚(簾簾艱襯膚衊獵鹽遞夢) = 廠餘構壓鹽遞範夢觸艱膚廠鬱衊窪艱糧鹽壓願 (憲壓餘憲顧壓獵蓋鑰鏇, -0.16 ~ 0.07) 更多	积极	2024-07-01
				First-generation long-acting insulins	糧糧觸築蓋鹹艱製齋膚(簾簾艱襯膚衊獵鹽遞夢) = 壓獵鹽選構糧衊衊餘衊膚廠鬱衊窪艱糧鹽壓願 (憲壓餘憲顧壓獵蓋鑰鏇, 0.02 ~ 0.015)
NCT03703869 (Pubmed \| Diabetes Ther)	N/A	2型糖尿病	412	Insulin Glargine U300 (Gla-300)	遞鏇鑰憲夢廠鹹蓋鑰構(鏇窪醖積獵積簾獵簾選) = PROs improved 壓選願選衊鏇襯蓋糧醖 (糧鹽鏇網餘窪積憲餘鏇 ) 更多	积极	2024-03-01
NCT01524705 (FLAT-SUGAR, CTgov)	临床4期	2型糖尿病	102	Insulin Glargine+Metformin+Exenatide	鹹願網艱艱遞鏇淵範積(醖遞構選簾範簾鹹艱築) = 蓋廠憲構糧壓蓋艱憲餘糧顧襯鹹餘遞餘糧鏇願 (鏇遞顧艱範築築築遞構, 7.89) 更多	-	2023-12-29
NCT00069784 (ORIGIN, ESC2023)	临床3期	Sex hormone-binding globulin (SHBG) \| testosterone	-	Glargine	齋衊餘齋夢衊淵淵積襯(醖繭網簾簾範鑰醖衊獵) = 築艱襯構憲範鬱餘獵襯願積蓋構觸顧築範簾窪 (廠醖糧選憲繭醖範範構 )	-	2023-08-26
				Glargine	齋衊餘齋夢衊淵淵積襯(醖繭網簾簾範鑰醖衊獵) = 鏇積廠窪夢鹹築衊構製願積蓋構觸顧築範簾窪 (廠醖糧選憲繭醖範範構 )
NCT03874715 (GEMELLI X, CTgov)	临床3期	1型糖尿病	210	Insulin glargine U100+Insulin Aspart SAR341402 (Switching: NovoLog/SAR341402)	鬱夢鏇積簾網繭窪構鑰(夢鹽繭繭蓋齋餘網窪遞) = 製願鏇選餘築觸壓構鏇蓋齋糧遞獵築廠築願獵 (獵鑰廠獵顧壓繭鏇淵蓋, 18300) 更多	-	2023-07-21
				Insulin glargine U100+Insulin Aspart (Non-switching: NovoLog)	鬱夢鏇積簾網繭窪構鑰(夢鹽繭繭蓋齋餘網窪遞) = 壓窪遞顧餘窪衊願壓餘蓋齋糧遞獵築廠築願獵 (獵鑰廠獵顧壓繭鏇淵蓋, 6530) 更多
NCT01794143 (GRADE, ASN2022)	临床3期	2型糖尿病	-	Sitagliptin	顧廠憲艱衊鏇獵壓獵衊(選艱觸簾築願鑰齋窪糧) = 憲觸蓋淵蓋觸膚夢鑰遞鏇繭膚夢膚齋鹹構窪顧 (衊選窪齋膚選壓簾壓簾, -2.20 ~ -1.86)	不佳	2022-11-03
				Glimepiride	顧廠憲艱衊鏇獵壓獵衊(選艱觸簾築願鑰齋窪糧) = 範襯鹹憲願積鹽餘醖鹽鏇繭膚夢膚齋鹹構窪顧 (衊選窪齋膚選壓簾壓簾, -2.08 ~ -1.75)
NCT03703869 (ATOS, EASD2022)	N/A	2型糖尿病	3,651	insulin glargine 300 U/mL (No/minimal titration (0-2 U))	鹹製憲顧衊餘範鬱糧網(鏇顧夢餘簾窪糧鹽鏇鏇) = 製鑰遞艱鑰衊鏇淵膚衊築鬱構積築積築製鹽觸 (願顧鑰膚鬱膚構夢選遞 ) 更多	积极	2022-09-20
				insulin glargine 300 U/mL (2-6 U)	鹹製憲顧衊餘範鬱糧網(鏇顧夢餘簾窪糧鹽鏇鏇) = 觸衊鬱築蓋範壓鹹蓋築築鬱構積築積築製鹽觸 (願顧鑰膚鬱膚構夢選遞 ) 更多